en · de · es
selank-notes.peptides3081.com › Guide › Identity And Structural Background — Hands-On Walkthrough

Identity And Structural Background — Hands-On Walkthrough

By Editorial Desk · published 2025-08-07 · last reviewed 2025-08-31 · Guide

This is a working overview of TKPRPGP, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2025-08-31. Anything still debated is marked as such rather than presented as settled.

Identity and Structural Background

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.

Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.

Background and Molecular Identity

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.

Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.

Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.

Selank at a glance

PropertyValueNotes
Chemical classSynthetic heptapeptideTuftsin analogue
SequenceThr-Lys-Pro-Arg-Pro-Gly-ProSingle-letter form: TKPRPGP
Molecular formulaC33H57N11O9Calculated for the free peptide
Molecular weightAbout 751.9 g/molDerived from the sequence
AppearanceWhite to off-white powderTypical lyophilised form

Proposed Mechanisms and Research Endpoints

Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.

Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.

Related pages on this site

Background and Peptide Identity

Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.

Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.

Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.

Selank Background and Peptide Chemistry

Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.

Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.

Peptide Identity and Structure

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.

The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.

Notes from published material

On April 5, the Iraqi government announced "the complete crushing of acts of sedition, sabotage and rioting in all towns of Iraq." An estimated 25,000 to 100,000 Iraqis were killed in the uprisings. In Kuwait, the Emir was restored, and suspected Iraqi collaborators were repressed. Eventually, over 400,000 people were expelled from the country, including a large number of Palestinians, because of PLO support of Saddam. Yasser Arafat did not apologize for his support of Iraq, but after his death Mahmoud Abbas formally apologized in 2004 on behalf of the PLO. This came after the Kuwaiti government formally forgave the group. There was some criticism of the Bush administration, as they chose to allow Saddam to remain in power instead of pushing on to capture Baghdad and overthrowing his government. In their co-written 1998 book, A World Transformed, Bush and Brent Scowcroft argued that such a course would have fractured the alliance, and would have had many unnecessary political and human costs associated with it. In 1992, the US defense secretary during the war, Dick Cheney, made the same point:

== External links == ELISA at the U.S. National Library of Medicine Medical Subject Headings (MeSH) "Introduction to ELISA Activity"—beginner walk-through of ELISA used for detecting HIV, including animations at the University of Arizona "ELISA Assay Principle" - An overview of the principle of an ELISA and tools for detecting analyties at Assay Genie

Trump stated that if he were elected, he would increase deportations, send the U.S. military to the border, expand U.S. Immigration and Customs Enforcement detentions through workplace raids, deputize local law enforcement to handle border security, increase U.S. Customs and Border Protection funding, as well as finish building the wall on the southern border. Trump has said he will deport both legal and illegal immigrants. The New York Times reported that Trump was considering "an extreme expansion of his first-term crackdown on immigration", such as "preparing to round up undocumented people already in the United States on a vast scale and detain them in sprawling camps while they wait to be expelled". Trump stated his intention to deport 11 million people through the construction of detention camps and deploy the military, relying on presidential wartime powers under the 18th-century Alien Enemies Act. Trump made false claims of a "migrant crime wave" that are not supported by data, and provided no evidence to back up his claims. In regards to his anti-immigrant nativism, Trump's tone grew harsher from his previous time as president, and used fearmongering, racial stereotypes, and more dehumanizing rhetoric when referring to illegal immigrants.

Sources: en.wikipedia.org

Further detail

== Pharmacokinetics == Tiapride is primarily taken orally in the form of a tablet, but can also be administered via intravenous or intramuscular injection. A liquid oral formulation is also available for elderly patients with difficulty chewing solids. For all three methods of administration, the bioavailability of tiapride is approximately 75 percent. Peak plasma concentrations are attained between 0.4 and 1.5 hours following administration, and steady-state concentrations achieved 24 to 48 hours after beginning administration 3 times a day. It distributes rapidly and exhibits virtually no binding to plasma proteins, giving it a relatively high volume of distribution. Benzamide and its derivatives are highly water-soluble, and because of their polarity are believed to cross the blood–brain barrier via carrier-mediated transport. Elimination of tiapride, mostly in its original form, occurs through renal excretion with a half-life of 3 to 4 hours. Recommended dosages of tiapride vary with clinical symptoms. In alcoholic patients, delirium or pre-delirium associated with alcohol withdrawal can be alleviated by administration of 400–1200 mg/day or up to 1800 mg/day if necessary. Tremors and other dyskinsias can be treated with 300–800 mg/day. For reducing agitation and aggression in elderly patients, 200–300 mg/day is recommended.

== Track listing == "Gone Fishing" - 3:46 "The Alphabet Song" - 4:07 "Another Girlfriend" - 3:01 "Paper Umbrella" - 4:17 "Unretractable Facts" - 3:29 "Play Fair" - 3:29 "The Wishbone" - 3:59 "Story With Only Two Characters" - 1:38 "Spilt Milk" - 4:56 "Moth To A Candle Flame" - 2:51 "Four Leaf Clover" - 4:39 "Shadow Of A Doubt" - 2:33 "Giant Steps (Bonus Track)" - 4:27

Vaping enthusiasts often begin with a cig-a-like first-generation device and tend to move towards using a later-generation device with a larger battery. Cig-a-likes and tanks are among the most popular devices. But tanks vaporize nicotine more effectively, and there are a greater selection of flavors and levels of nicotine, and are usually used by experienced users. Under five minutes of cig-a-like vaping, blood nicotine levels can elevate to about 5 ng/ml, while under 30 minutes of using 2 mg of nicotine gum, blood nicotine levels ranged from 3–5 ng/ml. Under five minutes of using tank systems by experienced vapers, the elevation in blood nicotine level can be 3–4 times greater. Many devices lets the user use interchangeable components, which result in variations in the e-cigarette vaporized nicotine. One of the primary features of the more recent generation of devices is that they contain larger batteries and are capable of heating the liquid to a higher temperature, potentially releasing more nicotine, forming additional toxicants, and creating larger clouds of particulate matter. A 2017 review found "Many e-cig users prefer to vape at high temperatures as more aerosol is generated per puff. However, applying a high voltage to a low-resistance heating coil can easily heat e-liquids to temperatures in excess of 300 °C; temperatures sufficient to pyrolyze e-liquid components."

DNA-binding domain (DBD) A protein domain containing at least one structural motif capable of recognizing and interacting with the nucleotides of a double-stranded or single-stranded DNA molecule. DNA-binding domains may bind to specific sequences or have a non-specific affinity for DNA. They are the primary functional components of DNA-binding proteins, including many transcription factors and regulatory proteins.

Sources: en.wikipedia.org

Frequently asked questions

What is the peptide sequence of Selank?

The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, commonly written as TKPRPGP. It shares the first four residues with tuftsin and carries three prolines in the chain. The proline-rich tail is the main structural feature that separates it from the parent tetrapeptide.

How is it related to tuftsin?

Selank is a synthetic analogue built on the tuftsin tetrapeptide Thr-Lys-Pro-Arg. Extra proline residues were added to the C-terminus during design work. That modification is intended to make the peptide less vulnerable to rapid enzymatic degradation.

Why do different sources use different names?

Transliteration from Russian produces variant spellings such as Selanc. Many suppliers avoid the trade-style name entirely and list the peptide sequence. Comparing sequences rather than names is the reliable way to confirm two entries describe the same molecule.

What is Selank chemically?

Selank is a seven-amino-acid peptide built from the tuftsin sequence plus a Pro-Gly-Pro tail. It is produced by chemical synthesis rather than extracted from a natural source. The free peptide is usually supplied as a lyophilised powder or in an aqueous formulation.

Network